Cargando…
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
The treatment for chronic myeloid leukemia has changed significantly over the past 15 years, and as of now, there are five BCR-ABL1 (breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1) tyrosine kinase inhibitors that have gained approval for treatment of this disease. All fiv...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099191/ https://www.ncbi.nlm.nih.gov/pubmed/25045255 http://dx.doi.org/10.2147/PPA.S53160 |